期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 153, 期 -, 页码 S428-S437出版社
WILEY
DOI: 10.1038/bjp.2008.2
关键词
glycogen synthase kinase; long-term potentiation; long-term depression; PI3K; Akt; PP1; NMDA receptor; AMPA receptor; metaplasticity; hippocampus
资金
- Medical Research Council [G0601813] Funding Source: Medline
- Wellcome Trust Funding Source: Medline
- MRC [G0601813] Funding Source: UKRI
- Medical Research Council [G0601813] Funding Source: researchfish
Glycogen synthase kinase-3 (GSK-3), an important component of the glycogen metabolism pathway, is highly expressed in the CNS. It has been implicated in major neurological disorders including Alzheimer's disease, schizophrenia and bipolar disorders. Despite its central role in these conditions it was not known until recently whether GSK-3 has neuronal-specific functions under normal conditions. However recent work has shown that GSK-3 is involved in the regulation of, and cross-talk between, two major forms of synaptic plasticity, N-methyl-D-aspartate receptor ( NMDAR)-dependent long-term potentiation (LTP) and NMDAR-dependent long-term depression (LTD). The present article summarizes this recent work and discusses its potential relevance to the treatment of neurological disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据